EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

医学 内科学 肺癌 肿瘤科 化疗 转移 脑转移 表皮生长因子受体 外显子 病历 癌症 基因 生物化学 化学
作者
Guangjian Yang,Jun Li,Haiyan Xu,Yaning Yang,Lu Yang,Fei Xu,Bing Xia,Viola W. Zhu,Misako Nagasaka,Yang Yan,LI Ya-pin,Weini Qiu,Jianming Ying,Sai‐Hong Ignatius Ou,Yan Wang
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:145: 186-194 被引量:91
标识
DOI:10.1016/j.lungcan.2020.03.014
摘要

To describe the treatment patterns and outcomes of Chinese non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in real-world as EGFR ex20ins consist of a diverse group of mutations with limited information on the clinical outcome of these patients treated with chemotherapy or EGFR tyrosine kinase inhibitors (TKIs).Real-world treatment outcomes of Chinese NSCLC patients harboring EGFR ex20ins were retrospectively analyzed based on medical records at different institutions and detailed web-based patient questionnaires.Between March 17, 2018 and December 20, 2018, 165 advanced EGFR ex20ins NSCLC patients treated in 99 hospitals from 26 different regions in China were analyzed. Thirty-nine different molecular variants of EGFR ex20ins were identified with V769_D770insASV being the most common (23.0 %). Central nervous system (CNS) metastasis occurred in 23.0 % of patients at the time of baseline diagnosis. Median progression-free survival (PFS) was significantly longer in patients who received first-line platinum-based chemotherapy (6.4 m; 95 % CI: 5.7-7.1) than all-generation EGFR TKIs (2.9 m; 95 %CI: 1.5-4.3; P < 0.001) or 1st-generation EGFR TKIs (2.0 m; 95 %CI: 0.2-3.8; P < 0.001). Median PFS was numerically longer in patients who received second-line chemotherapy (4.0 m; 95 %CI: 3.2-4.8) than those received second-line EGFR TKIs (2.0 m; 95 %CI: 1.1-2.9; P = 0.342). Patients with CNS metastasis had numerically shorter median PFS than those without CNS metastasis when treated with 1st-line chemotherapy (3.6 m; 95 %CI: 0-8.0 vs. 6.5 m; 95 %CI: 4.9-8.1; P = 0.645) or 1st-line EGFR TKIs (2.0 m; 95 %CI: 0.8-3.2 vs. 2.9 m; 95 %CI: 2.1-3.7; P = 0.058).Chemotherapy is superior to current approved EGFR TKIs as 1st- or 2nd-line treatment of EGFR ex20ins mutations. CNS metastasis conferred numerically shorter PFS with chemotherapy or EGFR TKIs treatment. Targeted agent against EGFR ex20ins with CNS activity is urgently needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晚风完成签到,获得积分10
1秒前
jwj发布了新的文献求助10
2秒前
2秒前
白熊完成签到 ,获得积分10
2秒前
3秒前
李健应助北齐冲浪的鱼采纳,获得10
4秒前
4秒前
王一鸣发布了新的文献求助10
5秒前
ikutovaya完成签到,获得积分10
5秒前
5秒前
奋斗的妙松完成签到,获得积分10
6秒前
老实莫言完成签到,获得积分10
6秒前
7秒前
量子星尘发布了新的文献求助150
7秒前
wop111应助morph采纳,获得20
7秒前
追寻的冬寒完成签到 ,获得积分10
8秒前
9秒前
吼吼吼吼发布了新的文献求助10
9秒前
善学以致用应助生动念烟采纳,获得10
9秒前
由天与发布了新的文献求助10
10秒前
wsy发布了新的文献求助10
11秒前
13秒前
15秒前
15秒前
16秒前
lllllll完成签到,获得积分10
17秒前
17秒前
王一鸣完成签到,获得积分10
18秒前
量子星尘发布了新的文献求助10
20秒前
心灵尔安完成签到 ,获得积分10
21秒前
你终硕发布了新的文献求助10
21秒前
科研通AI6应助满意的又蓝采纳,获得10
21秒前
jwj完成签到,获得积分10
22秒前
23秒前
大个应助gc529采纳,获得10
24秒前
25秒前
29秒前
所所应助你在烦恼什么采纳,获得10
30秒前
852应助你终硕采纳,获得10
30秒前
核桃发布了新的文献求助10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
NMR in Plants and Soils: New Developments in Time-domain NMR and Imaging 600
Electrochemistry: Volume 17 600
Physical Chemistry: How Chemistry Works 500
SOLUTIONS Adhesive restoration techniques restorative and integrated surgical procedures 500
Energy-Size Reduction Relationships In Comminution 500
Principles Of Comminution, I-Size Distribution And Surface Calculations 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4950711
求助须知:如何正确求助?哪些是违规求助? 4213460
关于积分的说明 13104286
捐赠科研通 3995337
什么是DOI,文献DOI怎么找? 2186837
邀请新用户注册赠送积分活动 1202090
关于科研通互助平台的介绍 1115359